Suppr超能文献

[强化维持治疗对晚期淋巴细胞白血病儿童及青少年预后的影响]

[Impact of intensified maintenance therapy on the prognosis of children and adolescents with advanced lymphoblastic lymphoma].

作者信息

Yang K B, Sun X F, Zhen Z Z, Lu S Y, Zhu J, Sun F F, Wang J, Huang J T, Chen R R, Ye L T, Liu Y, You Z Y

机构信息

State Key Laboratory of Oncology in Southern China; Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2017 Sep 14;38(9):778-783. doi: 10.3760/cma.j.issn.0253-2727.2017.09.009.

Abstract

To investigate the impact of intensified maintenance therapy on the prognosis of children and adolescents with advanced lymphoblastic lymphoma (LBL) . Retrospective analysis on the treatment results of children and adolescents with stage Ⅲ and stage Ⅳ LBL who underwent BFM-NHL-90/-95 regimen without prophylactic radiotherapy. The intensified therapy group included the patients admitted from 1998 to 2005, while others were classified as the non-intensified therapy group. Patients in the intensified therapy group were intravenously treated with "etoposide phosphate plus cytrarabine" and high-dose methotrexate alternately per 2.5-3 months in addition to the oral chemotherapy with 6-mercaptopurine and methotrexate during the maintenance phase. A total of 187 LBL patients were enrolled. The rates of 5-year event free survival were (76.9 ± 5.8) % and (77.9 ± 4.3) % ((2)=0.249, =0.617) respectively, in the intensified therapy (=52) and the non-intensified therapy groups (=135) , while the rates of 5-year overall survival of them were (78.8 ± 5.7) % and (79.8±4.1) % ((2)=0.353, =0.552) , respectively. Stratified by stage, immunological type as well as risk stratification, the rates of long-term survival were similar between the two groups. During the maintenance phase, the rates of grade Ⅲ and Ⅳ myelosuppression in the intensified therapy and the non-intensified maintenance groups were 55.8% and 18.5%, respectively ((2)=25.363, <0.05) . Intensified maintenance therapy failed to improve the prognosis of patients with advanced LBL.

摘要

探讨强化维持治疗对晚期淋巴细胞白血病(LBL)儿童及青少年预后的影响。对接受BFM-NHL-90/-95方案且未进行预防性放疗的Ⅲ期和Ⅳ期LBL儿童及青少年的治疗结果进行回顾性分析。强化治疗组包括1998年至2005年入院的患者,其他患者归为非强化治疗组。强化治疗组患者在维持期除口服6-巯基嘌呤和甲氨蝶呤进行化疗外,每2.5 - 3个月交替静脉注射“磷酸依托泊苷加阿糖胞苷”及大剂量甲氨蝶呤。共纳入187例LBL患者。强化治疗组(n = 52)和非强化治疗组(n = 135)的5年无事件生存率分别为(76.9 ± 5.8)%和(77.9 ± 4.3)%(χ² = 0.249,P = 0.617),而两组的5年总生存率分别为(78.8 ± 5.7)%和(79.8 ± 4.1)%(χ² = 0.353,P = 0.552)。按分期、免疫类型及危险分层分析,两组的长期生存率相似。在维持期,强化治疗组和非强化维持组Ⅲ级和Ⅳ级骨髓抑制发生率分别为55.8%和18.5%(χ² = 25.363,P < 0.05)。强化维持治疗未能改善晚期LBL患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b7d/7348356/8a69829c5f55/cjh-38-09-778-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验